Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2007-03-06
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S381000, C544S391000
Reexamination Certificate
active
10655393
ABSTRACT:
Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
REFERENCES:
patent: 3288795 (1966-11-01), Irikura et al.
patent: 4188485 (1980-02-01), Kukla
patent: 4918073 (1990-04-01), Rüger et al.
patent: 5386025 (1995-01-01), Jay et al.
patent: 5391552 (1995-02-01), Inazu et al.
patent: 5428038 (1995-06-01), Chatterjee et al.
patent: 5623051 (1997-04-01), Catterall et al.
patent: 5646149 (1997-07-01), Hellberg et al.
patent: 5703071 (1997-12-01), Itoh et al.
patent: 5866574 (1999-02-01), Okamura et al.
patent: 6011035 (2000-01-01), Snutch et al.
patent: 6294533 (2001-09-01), Snutch et al.
patent: 6310059 (2001-10-01), Snutch
patent: 6387897 (2002-05-01), Snutch
patent: 6458781 (2002-10-01), Connor et al.
patent: 6492375 (2002-12-01), Snutch
patent: 6617322 (2003-09-01), Snutch
patent: 6943168 (2005-09-01), Snutch et al.
patent: 6949554 (2005-09-01), Snutch et al.
patent: 6951862 (2005-10-01), Snutch et al.
patent: 2001/0029258 (2001-10-01), Snutch
patent: 2004/0034035 (2004-02-01), Snutch et al.
patent: 2004/0147529 (2004-07-01), Snutch et al.
patent: 17385 (1973-11-01), None
patent: 2335461 (1999-06-01), None
patent: 2394327 (2001-06-01), None
patent: 0 187 524 (1986-07-01), None
patent: 0 213 006 (1987-03-01), None
patent: 0 458387 (1991-11-01), None
patent: 0 496 691 (1992-07-01), None
patent: 504 202 (1983-01-01), None
patent: 514 167 (1983-04-01), None
patent: 8 304 135 (1983-05-01), None
patent: 8 305 343 (1983-07-01), None
patent: 920 416 (1963-03-01), None
patent: 1 513 883 (1978-06-01), None
patent: WO 94/14786 (1994-07-01), None
patent: WO-97/24328 (1997-07-01), None
patent: WO-99/06383 (1999-02-01), None
patent: WO 99/15129 (1999-04-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 00/01375 (2000-01-01), None
patent: WO 00/18402 (2000-04-01), None
patent: WO 00/37059 (2000-06-01), None
patent: WO 01/45709 (2001-06-01), None
patent: WO-01/49670 (2001-07-01), None
patent: WO-03/068759 (2003-08-01), None
patent: WO-03/76421 (2003-09-01), None
Cao et al., Journal of Medicinal Chemistry (1992) 46(13):2589-2598.
International Search Report for PCT/CA2005/000544, mailed on Aug. 24, 2005, 7 pages.
Korzycka et al., Polish Journal of Pharmacology and Pharmacy (1986) 38(5-6):545-553.
International Search Report for PCT/CA2004/000535, mailed on Jul. 1, 2004, 5 pages.
Invitation to Pay Additional Fees for PCT/CA2004/000539, mailed on Sep. 2, 2004, 6 pages.
Boger et al., Helvetica Chimica Acta (2000) 83(8):1825-1845.
International Search Report for PCT/CA2004/000539, mailed on Dec. 22, 2004, 9 pages.
International Search Report for PCT/CA2004/001629, mailed on Jan. 21, 2005, 6 pages.
Jamieson et al., Synlett (2000) 11:1603-1607.
Toldy et al., Acta Chimica Academiae Scientiarum Hungarica (1965) 44:301-325.
Webster et al., Journal of the Chemical Society (2001) 14:1673-1695.
Bourinet et al., “Splicing of α1ASubunit Gene Generates Phenotypic Variants of P- and Q-Type Calcium Channels,”Nature Neuroscience(1999) 2:407-415.
Chiarini, A. et al., “1,4-Dihydropyridines Bearing a Pharmacophoric Fragment of Lidoflazine,” (1996).Bioorg&Med Chemistry4(10):1629-1635.
Cohan et al., “Depolarization-Induced Presynaptic Calcium Accumulation May Occur by an N-Type Channel that is Blocked by Flunarizine,”Annals of the New York Academy of Sciences(1991) 635:397-399.
Cribbs et al., “Cloning and Characterization of α1H from Human Heart, A Member of the T-Type Ca2+Channel Gene Family,”Circulation Research(1998) 83:103-109.
Database WPI Week 9711 Derwent Publications Ltd., London, GB; Abstract JP 09 003067, XP002133055 (Hisamitsu Pharm Co Ltd.) Jan. 7, 1997.
De Waard et al., “Structural and Functional Diversity of Voltage-Activated Calcium Channels,” ION CHANNELS (Narahashi, T. ed. Plenum Press, NY 1997) 4:41-87.
Dhainaut et al., “New Triazine Derivatives as Potent Modulators of Multidrug Resistance,”J Med Chem(1992) 35:2481-2496.
Dooley, “Lomerizine Kanebo KK”Current Opinion in CPNS Investigational Drugs(1999) 1(1):116-125.
Dunlap et al., “Exocytotic Ca2+Channels in Mammalian Central Neurons,”Trends Neuroscience(1995) 18:89-98.
Estep et al., “Synthesis and Structure-Activity Relationships of 6-Heterocyclic-Substituted Purines as Inactivation Modifiers of Cardiac Sodium Channels,”J Med Chem(1995) 38:2582-2595.
Galizzi et al., “Neuroleptics of the Diphenylbutylpiperidine Series are Potent Calcium Channel Inhibitors,”Proc Natl Acad Sci USA(1986) 83: 7513-7517.
Glamkowski et al., “Synthesis of 3-(4-Acylaminopiperazin-1-ylalkyl) Indoles as Potential Antihypertensive Agents,”J Med Chem(1977) 20(11):1485-1489.
Gould et al., “Antischizophrenic Drugs of the Diphenylbutylpiperidine Type Act as Calcium Channel Antagonists,”Proc Natl Acad Sci(1983) 80:5122-5125.
Grantham et al., “Fluspirilene Block of N-Type Calcium Current in NGF-Differentiated PC12 Cells,”Brit J Pharmacol(1994) 111:438-488.
Ito et al., “U-92032, a T-Type Ca+Channel Blocker and Antioxidant, Reduces Neuronal Ischemic Injuries,”Eur J Pharmacol(1994) 257:203-210.
King et al., “Substituted Diphenylbutylpiperidines Bind to a Unique High Affinity Site on the L-Type Calcium Channel,”J Biol Chem(1989) 264:5633-5641.
Lee et al., “Cloning and Expression of a Novel Member of the Low Voltage-Activated T-Type Calcium Channel Family,”J of Neurosci(1999) 19:1912-1921.
Lehmann et al., “Zur Struktur und Pharmakologies γ-lactonverbruckter Diphenylalkylamine,”Arch Pharm(1988) 321:807-812.
“Lomerizine Kanebo KK,” published in Current Opinion in CPNS Investigational Drugs (1999) 1(1):116-125.
McCleskey et al., “Functional Properties of Voltage Dependent Calcium Channels,”Curr Topics(1991) 39:295-326.
Miyano et al., “The Synthesis and Antilipidperoxidation Activity of 4,4-diarylbutylamines and 4,4-diarylbutanamides,”Chem Pharm Bull(1990) 38(6):1570-1574.
Ohtaka et al., “Benzylpiperazine Derivatives. V. Quantitative Structure-Activity Relationships of 1-Benzyl-4-diphenylmethylpiperazine Derivatives for Cerebral Vasodilating Activity,”Chem Pharm Bull(1987) 35(10):4117-4123.
Ohtaka et al., “Benzylpiperazine Derivatives. IV. Syntheses and Cerebral Vasodilating Activities of 1-Benzyl-4-diphenylmethyl-piperazine Derivatives,”Chem Pharm Bull(1987) 35(8):3270-3275.
Perez-Reyes et al., “Molecular Characterization of a Neuronal Low-Voltage-Activated T-Type Calcium Channel,”Nature(1998) 391:896-900.
Prasad et al., “Potential Antihypertensive Agents. II. Unsymmetrically 1.4-disubstituted Piperazines,”J Med Chem(1968) 11(6):1144-1150.
Sather et al., “Distinctive Biophysical and Pharmacological Properties of Class A (BI) Calcium Channel α1Subunits,”Neuron(1993) 11:291-303.
Stea et al., “Localization and Functional Properties of a Rat Brain α1ACalcium Channel Reflect Similarities to Neuronal Q- and P-Type Channels,” Proc Natl Acad Sci USA (1994) 91:10576-10580.
Stea et al., Handbook of Receptors and Channels (North, R.A. ed. CRC Press 1995) 113-151.
Tytgat et al., “Flunarizine Inhibits a High-threshold Inactivating Calcium Channel (N-type) in Isolated Hippocampal Neurons,”Brain Research(1991) 549:112-117.
Uneyama et al., “Non-L-type Actions of Organic Ca2+Channel Blockers: Implications for Na+and N-type Ca2+Channels Blockades,”Calcium Ion Modulators, Sel Pap Satell Symp(1988) 13-23.
Vadodaria et al., “Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives and Related Compounds. II,”J Med Chem(1969) 12:860-865.
Zikolova et al., “Analogs of N1-benzhydryl-N4-cinnamylpiperazine (cinnarizine). II. N1-substituted-N4-benzhydrylpiperazines,”Tr Nauchnoizsled Khim—Farm Inst(1972) 8:59-67 (Database Chemabs 'Online! Chemical Abstracts Service, Co
Belardetti Francesco
Pajouhesh Hassan
Pajouhesh Hossein
Snutch Terrance P.
Zamponi Gerald W.
Henley III Raymond J.
Morrison & Foerster / LLP
Neuromed Pharmaceuticals Ltd.
LandOfFree
Preferentially substituted calcium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preferentially substituted calcium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preferentially substituted calcium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767356